Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Edwards Lifesciences Corporation before investing.

In this article, we go over a few key elements for understanding Edwards Lifesciences Corporation’s stock price such as:

• Edwards Lifesciences Corporation’s current stock price and volume
• Why Edwards Lifesciences Corporation’s stock price changed recently
• Upgrades and downgrades for EW from analysts
• EW’s stock price momentum as measured by its relative strength

About Edwards Lifesciences Corporation (EW)

Before we jump into Edwards Lifesciences Corporation’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Want to learn more about Edwards Lifesciences Corporation’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Edwards Lifesciences Corporation.

Edwards Lifesciences Corporation’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Edwards Lifesciences Corporation’s stock price was $86.070.

Edwards Lifesciences Corporation is down 0.98% from its previous closing price of $86.920.

During the last market session, Edwards Lifesciences Corporation’s stock traded between $85.240 and $87.080. Currently, there are approximately 579.20 million shares outstanding for Edwards Lifesciences Corporation.

Edwards Lifesciences Corporation’s price-earnings (P/E) ratio is currently at 46.7, which is high compared to the Health Care Equipment & Supplies industry median of 31.1. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Edwards Lifesciences Corporation Stock Price History

Edwards Lifesciences Corporation’s (EW) price is currently down 4.85% so far this month.

During the month of July, Edwards Lifesciences Corporation’s stock price has reached a high of $96.290 and a low of $81.155.

Over the last year, Edwards Lifesciences Corporation has hit prices as high as $96.290 and as low as $72.300. Year to date, Edwards Lifesciences Corporation’s stock is up 0.96%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Edwards Lifesciences Corporation Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there was 1 analyst who downgraded Edwards Lifesciences Corporation’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Edwards Lifesciences Corporation’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Edwards Lifesciences Corporation’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Edwards Lifesciences Corporation’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Edwards Lifesciences Corporation (EW) by visiting AAII Stock Evaluator.

Relative Price Strength of Edwards Lifesciences Corporation

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Edwards Lifesciences Corporation has a weighted four-quarter relative price strength of -1.90%, which translates to a Momentum Score of 46 and is considered to be Average.

Want to learn more about how Edwards Lifesciences Corporation is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Edwards Lifesciences Corporation Stock Price: Bottom Line

As of July 31, 2026, Edwards Lifesciences Corporation’s stock price is $86.070, which is down 0.98% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Edwards Lifesciences Corporation stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.